ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 225,80
0,20%
Dow Jones
39 558,11
0,32%
DAX
18 716,42
-0,12%
Brent Oil
82,49
-0,07%
Bitcoin
61 388,17
-0,25%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) Actualités

RNAZ TransCode Therapeutics Inc

0,77
0,1538 (24,96%)
15 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
TransCode Therapeutics Inc RNAZ NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,1538 24,96% 0,77 01:58:54
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,55 0,4222 0,85 0,7301 0,6162
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/5/202423:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/5/202414:30GLOBETransCode Therapeutics Open Letter to Shareholders
10/5/202422:50EDGAR2Form PRE 14A - Other preliminary proxy statements
10/5/202422:45EDGAR2Form 8-K - Current report
15/4/202415:00GLOBETransCode Therapeutics Announces FDA Clearance To Initiate..
03/4/202415:10GLOBETransCode Therapeutics Reports 2023 Results; Provides..
28/3/202413:30GLOBETransCode Therapeutics Announces Appointment of Daniel..
11/3/202414:00GLOBETransCode Therapeutics and Akribion Genomics Report Progress..
06/3/202422:15GLOBETransCode Therapeutics To Present At 2024 RNA Leaders Europe..
20/2/202414:00GLOBETransCode Therapeutics Reports Publication of United States..
15/2/202422:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202402:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202422:33EDGAR2Form 8-K - Current report
31/1/202422:05GLOBENasdaq Determines TransCode Therapeutics Compliance with..
29/1/202414:30GLOBETransCode Therapeutics and Debiopharm Announce Collaboration..
22/1/202422:45EDGAR2Form 8-K - Current report
22/1/202422:45GLOBETransCode Therapeutics Announces Closing of $7.25 Million..
20/1/202403:57EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
19/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
18/1/202419:27GLOBETransCode Therapeutics Announces Pricing of $7.25 Million..
18/1/202416:39EDGAR2Form S-1/A - General form for registration of securities..
17/1/202413:06EDGAR2Form S-1/A - General form for registration of securities..
16/1/202422:01EDGAR2Form 8-K - Current report
12/1/202422:05GLOBETransCode Therapeutics Reports Further Restructuring to..
11/1/202414:22EDGAR2Form S-1 - General form for registration of securities under..
11/1/202414:00GLOBETransCode Therapeutics Announces 1-for-40 Reverse Stock..
08/1/202422:01EDGAR2Form 8-K - Current report
04/1/202418:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/1/202414:05GLOBETransCode Therapeutics Publishes Open Letter Outlining..
18/12/202322:28EDGAR2Form DEF 14A - Other definitive proxy statements
12/12/202314:30GLOBETransCode Therapeutics Reports Positive Pre-Clinical Results..
08/12/202322:57EDGAR2Form PRE 14A - Other preliminary proxy statements
08/12/202322:56EDGAR2Form 8-K - Current report
07/12/202322:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/12/202315:00GLOBETransCode Therapeutics To Present Phase 0 Data at 2023 San..
04/12/202323:07EDGAR2Form 8-K - Current report
04/12/202322:10GLOBETransCode Therapeutics Announces Closing of $1.2 Million..
01/12/202323:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/11/202320:53GLOBETransCode Therapeutics Announces $1.2 Million Registered..
14/11/202322:40EDGAR2Form 8-K - Current report
14/11/202322:30GLOBETransCode Therapeutics Reports Third Quarter 2023 Results;..
09/11/202322:13EDGAR2Form 8-K - Current report
01/11/202303:20APSBiotech Shares Bid Up Following Public Offering Cancellation
30/10/202321:33GLOBETransCode Therapeutics Withdraws Public Offering
27/10/202322:06EDGAR2Form 8-K - Current report
27/10/202314:00GLOBENasdaq Panel Grants TransCode Therapeutics Extension for..
26/10/202322:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/10/202322:19GLOBETransCode Therapeutics Announces Public Offering of Common..
26/10/202314:00GLOBETransCode Therapeutics Announces Prolonged Survival in..
24/10/202314:05EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
RNAZ
TransCode Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés